An open-label study of the efficacy of atomoxetine hydrochloride on quality of life of children and adolescents with attention-deficit/hyperactivity disorder with or without comorbid conditions

Trial Profile

An open-label study of the efficacy of atomoxetine hydrochloride on quality of life of children and adolescents with attention-deficit/hyperactivity disorder with or without comorbid conditions

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2010 Actual patient number changed from 267 to 269 as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Status changed from recruiting to in progress according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top